On June 30, 2025, Biofrontera Inc. finalized an agreement with Biofrontera AG to acquire U.S. rights for medicines Ameluz® and RhodoLED®, paying a 12-15% royalty based on sales, along with issuing shares worth 3,109 Series D Preferred Stock to Biofrontera AG. Additionally, on June 27, 2025, they began a private placement for up to $11 million in Series C Preferred Stock to fund this transaction.